GCGR and diabetes mellitus: As shown in Figure 4, volagidemab (REMD-477) is a humanized glucagon receptor monoclonal antibody (GCGR mAb) that is being investigated for its therapeutic potential in diabetes because it antagonizes the glucagon receptor and may be able to prevent these negative effects of hyperglucagonemia [53].